No Data
No Data
Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $20
Cogent Biosciences Reaches Alignment With US FDA to Use Patient-Reported Symptom Tracking in Trial
Express News | Cogent Biosciences Inc: Remain on Track to Complete Enrollment in Summit Part 2 in Q2 of 2025 and Report Top-Line Results by Year-End 2025
Express News | Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the Summit Trial
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $19
Express News | Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target